The database health industry of BIOPRO Baden-Württemberg GmbH lists concise profiles of biotech-, medtech and pharma companies in Baden-Württemberg. The database includes companies, that are involved in research, development and/or production. The "free text search" option allows you to search in all profiles and data. You may, however, also limit your search to specific categories. The categorization of the companies is carried out by BIOPRO and not based on a self-assessment of the companies. Please contact datenbank(at)bio-pro.de - if your company is missing in our database or if you would like to leave a comment on our database.
The database provides concise information on research institutions active in the Baden-Württemberg healthcare and bioeconomy sectors. You can use either the “free text“ search option to search all profiles in the database or limit your search to specific categories. If you have any questions, please contact us at: datenbank(at)bio-pro.de.
The processing and packaging of food is governed by very strict hygiene rules. Researchers are now testing production equipment for cleanroom suitability and are listing qualified products in an online database.
In the healthcare sector, blockchain technology is still in the early stages of development, although it has huge potential in this field. It is expected that patients will particularly benefit from the introduction of a decentralised database for managing and sharing health-related information with treating physicians. Statutory health insurance companies become less important as intermediaries. But how exactly does this technology work?
ChEMBLdb a vast online database of information on the properties and activities of drugs and drug-like small molecules and their targets was launched on January 18 2010 with information on over half a million compounds. The data lie at the heart of translating information from the human genome into successful new drugs in the clinic.
New databases and bioinformatic tools provide the field of glycomics with a solid basis for dynamic development in molecular biology and medicine. Willi von der Lieth a researcher from Heidelberg was an important pioneer of glyco-bioinformatics. His sudden death is a great loss for this new scientific field.
Databases are classical tools for the collection, administration and presentation of computer data in table form. Tübingen-based Hölle & Hüttner AG has developed a completely new solution – H-Maps: a semantic knowledge matrix that associates and represents information as clearly arranged networks. This gives users a rapid overview and enables them to recognise new relationships.
In order to be able to manage the growing amount of information in the life sciences the international research community has developed numerous electronic databases over the last few years. Supported by sophisticated software programmes the stored information can now be analysed effectively. In parallel with work-intensive screening methods which involve many laboratory experiments scientists are increasingly relying on computer-based methods.
On 1st December 2008 Prof. Dr. Karl Schmid the first person to hold the F.W. Schnell Foundations endowed professorship for crop biodiversity and breeding informatics started the ball rolling on a unique European-wide project. Schmid and his colleagues are searching gigantic databases in which genetic analyses and plant descriptions are stored for hidden treasures.
The bachelor’s theses of Matthias Hillert and Pascal Laube, students at the Konstanz University of Applied Sciences (HTWG), involved the development of a computer programme that facilitates the analysis of computed tomography images of the liver by comparing them to similar images stored in a database. It is a tool that has the potential to be used in other areas, such as the identification of bone tumours.
On 22nd January 2010, the first German Treatment and Research Centre of Rare Diseases (ZSE) was officially opened in Tübingen. Interdisciplinary teams will from now on be developing new therapies under one roof for around three to four million patients suffering from rare diseases in Germany. The centre in Tübingen will offer optimal patient treatment, coordinate the cooperation between international specialists, and provide competent advice and information. In addition, the centre will also establish a central biomaterial database and a register.
Insilico Biotechnology AG from Stuttgart designs and optimises biotechnological processes for the chemical pharmaceutical and food industries. The company makes predictions on the behaviour of cells and organisms. This knowledge can be used to reduce the time required for the development or optimisation of biotechnological processes involving the production of drugs. The company owns a worldwide unique systems biology platform that integrates proprietary databases cell models and computer-assisted analysis methods. Insilico offers new solutions based on the integration and analysis of experimental data using genome-wide network models for the production of biochemicals and biopharmaceuticals as well as for the validation of active substances.
Human biobanks are treasure troves for medical research. Although the majority of these repositories were set up with public funds up until now they have only allowed external researchers limited access to information and samples. This will change from 22nd November 2010 when the first six German biobanks hold their inaugural meeting in Berlin to discuss and organise the establishment of the German Biobank Registry Project Portal.
Prof. Michael Berthold has an ideal colleague in mind this person has been with the company for decades knows everybody has read every important document has seen all the experiments and talked to everybody. This ideal colleague is actually a projected software system.
The two GlobalFlow GmbH managing directors, Nadine Antic and Seda Erkus, only recently completed their energy and resource management and environmental technology studies and immediately set out to establish their own company. GlobalFlow GmbH, which is based in Reutlingen, offers comprehensive services related to the conservation of resources and materials management.
„Window-to-Japan“ is a service of Bio4Business, a provider of project support and technology scouting. “Window-to-Japan” offers customized information on Japanese bio-research and bio-business, largely based on information in Japanese language. Stay up-to-date with the newsletter, free of charge.
Medical technology is indispensible for human health and contributes a great deal to improving the quality of our lives. The field of medical technology covers many areas. These range from simple disposable products and consumables such as dressing materials and other clinical supplies, to IT-related telemedicine, homecare and eHealth systems as well as high-technology and innovative robotics, imaging, diagnostics and life-support systems. 818 companies research, develop and/or produce in Baden-Württemberg, which makes it one of the leading locations in this field in Europe.
Scientists have long dreamed of being able to grasp the brain as a whole. A research team led by Junior Professor Dr. Olaf Ronneberger from the Department of Computer Science of the University of Freiburg and Prof. Dr. Wolfgang Driever developmental biologist at the Institute of Biology I has now taken a big step toward making this dream a reality. The Freiburg researchers developed microscopic imaging techniques and software for observing and comparing all of the genes of the zebrafish brain and thus also the factors influencing its nerve cells in a three-dimensional virtual model.
The Bioware team from Freiburg, an important part of the bioss cluster of excellence, has once again achieved resounding success: one gold medal and two special prizes at the iGEM competition (international Genetically Engineered Machine), the largest event for up-and-coming scientists focusing on synthetic biology. It was the turn of the research group heads, junior professor Dr. Kristian Müller and Dr. Katja Arndt, to participate in the competition with two teams, making it into the final round and showing that their Bioware and Software teams are among the six best biotech hubs in the world.
The AIDS virus (HIV) inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.
Stuttgart-based Nexxor GmbH uses its topicWorks platform as a basis for developing “knowledge-oriented” information systems specifically for the pharmaceutical, biotech and life science sectors. These standardised software systems are no longer based solely on data and documents. They employ an innovative concept to map the meanings and semantic relationships of content in a flexible way, similar to processes used by the Semantic Web.
Spectroscopic methods have been used for many decades in scientific research to obtain a wealth of information about chemical substances, substance mixtures and their reaction processes. Micro-biolytics GmbH from Esslingen have successfully developed a spectroscopic method that combines innovative technologies. The method enables the highly accurate and sensitive measurement of aqueous samples.
Protein building blocks with well-defined properties that can be assembled into new molecules with desired structures and functions are highly sought after in biotechnology and medicine. Birte Höcker, a biologist at the Max Planck Institute for Developmental Biology in Tübingen, is currently working on this in a project she calls “Protein Lego”.
Researchers at the Heidelberg Institute for Theoretical Studies HITS are part of the national Virtual Liver Network initiated and financed by the German Federal Ministry of Education and Research BMBF.
Since January 2015, Tübingen has been home to a Centre for Personalised Medicine (ZPM). Twenty-three institutes and hospitals have joined forces to improve diagnosis of disease and develop individualised treatments for patients with a variety of diseases. In parallel, the centre also develops new diagnostic strategies. This means, for example, that data derived from the analysis of the entire genetic material of cells, proteins and metabolic processes are taken into account when stratifying patient therapy.